REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care
A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 500 participants.
Also called NCT07853716
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 500 participants
- Sponsor
- Registry
-
NCT07853716
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07853716. Randomized; no masking; primary purpose prevention. Start 2026-11 (anticipated); primary completion 2029-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care
- Acronym
- REFINE-CAC
- Intervention (Device)
- Heartflow Analysis
- Lead sponsor
- HeartFlow, Inc.
- Collaborator
- Avania
Record details
- Record id
cardio:ct-nct07853716- Content hash
4ee7ae81e5ad7d50b5364832991cd63749f9100a99e43cdf41153ceb4d143db6